Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Lin, Heng; Li, Lina; Luo, Shuimei; Zhou, Sijing; Shen, Ruifen; Huang, Yang; Chen, Huijuan; Xie, Xianhe

doi:10.18632/oncotarget.13588

Cited by 13 publications

(6 citation statements)

References 37 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, a meta-analysis has shown that the addition of anti-angiogenic drugs would increase the risks of common AEs, such as pain, hypertension, gastrointestinal symptom, metabolic disorders, and neurology. 15 Notably, the safety profile in this study was similar to that of Rh-endostatin or irinotecan/cisplatin monotherapies. These reported AEs were known and also resulted from the nedaplatin/paclitaxel regimen alone, 11 suggesting that the Rh-endostatin may not increase the risks of toxicity in this population.…”

Section: Assessment Analysis and Discussionsupporting

confidence: 53%

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Sun

Zhao

et al. 2022

The Oncologist

View full text Add to dashboard Cite

Background This open-label, phase II study aimed to investigate the efficacy and safety of recombinant human endostatin (Rh-endostatin) plus irinotecan/cisplatin as second-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). Methods Eligible patients received 15mg/m2 Rh-endostatin as a continuous intravenous pump infusion (7 continuous days), 60mg/m2 irinotecan (days 1 and 8), and 60mg/m2 cisplatin (day 1) every 3 weeks. The primary endpoint was progression-free survival (PFS). Results A total of 50 patients were assessable for efficacy and safety analysis. The median follow-up was 10.97 months (95%CI: 7.03-19.42) as the data cutoff. Median PFS was 4.01 months (95% CI: 3.19-5.49), and median overall survival (OS) was 12.32 months (95% CI: 8.21-17.45); 13 (26%; 95% CI: 15.87-39.55) of 50 patients had an objective response, and 31 (62%; 95% CI: 48.15-74.14) had disease control. Grade 3 or greater treatment-related adverse events (AEs) occurred in 12 (24.0%) patients, and no deaths were reported. The common grade 3 or greater AEs were leucopenia (18.0%) and neutropenia (16.0%). Five (10%) patients discontinued treatment because of AEs. Conclusion Rh-endostatin plus irinotecan/cisplatin showed promising anti-tumor activity in advanced ESCC patients with a good safety profile in the second-line setting, which warrants further study in this population. (ClinicalTrials.gov identifier: NCT03797625).

show abstract

Section: Assessment Analysis and Discussionsupporting

confidence: 53%

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Sun

Zhao

et al. 2022

The Oncologist

View full text Add to dashboard Cite

show abstract

“…[40] In this study, the pooled results revealed that angiogenesis inhibitors did not improve OS [HR = 0.99 (95% CI 0.88–1.12), P = 0.91], PFS [HR = 0.87 (95% CI 0.74–1.02), P = 0.09] or ORR [HR = 0.94 (95% CI 0.74–1.19), P = 0.89].…”

Section: Discussionmentioning

confidence: 78%

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC)

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…In particular, VEGF-A levels have been demonstrated to directly correlate with the microvessel density. Consistently, the combination of angiogenesis inhibitors, like bevacizumab or ziv-aflibercept, with traditional chemotherapy, significantly improved the overall response rate (ORR) and progression-free survival (PFS) of patients with SCLC [98].…”

Section: Lung Cancermentioning

confidence: 89%

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Ceci

Atzori

Lacal

et al. 2020

IJMS

175

View full text Add to dashboard Cite

The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated angiogenesis, tissue infiltration, and metastasis formation. Although VEGF-A can activate both VEGFR-1 and VEGFR-2 membrane receptors, PlGF and VEGF-B exclusively interact with VEGFR-1. Differently from VEGFR-2, which is involved both in physiological and pathological angiogenesis, in the adult VEGFR-1 is required only for pathological angiogenesis. Besides this role in tumor endothelium, ligand-mediated stimulation of VEGFR-1 expressed in tumor cells may directly induce cell chemotaxis and extracellular matrix invasion. Furthermore, VEGFR-1 activation in myeloid progenitors and tumor-associated macrophages favors cancer immune escape through the release of immunosuppressive cytokines. These properties have prompted a number of preclinical and clinical studies to analyze VEGFR-1 involvement in the metastatic process. The aim of the present review is to highlight the contribution of VEGFs/VEGFR-1 signaling in the progression of different tumor types and to provide an overview of the therapeutic approaches targeting VEGFR-1 currently under investigation.

show abstract

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Cited by 13 publications

References 37 publications

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC)

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Contact Info

Product

Resources

About